The UK and US have hammered out a significant trade agreement that will keep no tariffs on British medicine products going into the American market.
Key Provisions of the Deal
As part of the deal, the UK has agreed to increase spending on medicines through the National Health Service (NHS). This commitment secures that tariffs on these vital goods will stay at nothing for a timeframe of the next three years.
This agreement is in response to earlier warnings to significantly raise import taxes on branded pharmaceutical products, with figures mentioned as high as one hundred percent.
"This deal between the Britain bolsters the international landscape for cutting-edge drugs and establishes long-overdue balance to U.S.–U.K. pharmaceutical trade," a release said.
Commercial Significance
Drugs are one of the the United Kingdom's biggest export categories to the America, which is easily the largest destination for major British pharmaceutical firms.
Trade data indicate that in the year to the end of the third quarter, the UK exported pharmaceutical products worth £11.1bn to the US. This amount represented nearly one-fifth of total UK exports in that period.
"This guarantee safeguards employment, boosts investment and facilitates the UK to establish itself as a international leader for biotech and pharma," a minister commented.
Specific British Pledges
The agreement includes several key pledges from the UK:
- Revised Affordability Limit: The UK will increase the price threshold at which it judges new therapies to be unaffordable by a quarter.
- Increased NHS Spending: There is a aim to double total health service expenditure on medicines from 0.3% of the national economy to 0.6 percent over the coming ten years.
- Refund Ceiling: The percentage drug companies must refund to the NHS to control costs will be limited at 15%. Last year, rebates were more than twenty percent.
Broader Context
This agreement comes amid a long-running dispute between the sector and the British authorities over medicine costs and NHS adoption.
These tensions were intensified by assertions that American customers were charged a premium for the same drugs than consumers in the UK and Europe.
Recently, several large manufacturing plans in the UK have been halted or abandoned, while major investments have been directed toward American operations.
One official acknowledged that the NHS needed to increase expenditure on drugs, noting that its spending on drugs had decreased as a percentage of its overall budget over the past decade.
